ArticleAnnals of intensive care2016
Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock.
Article in Annals of intensive care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Systematic review of high-dose amikacin regimens for the treatment of Gram-negative infections based on EUCAST dosing recommendations.European journal of hospital pharmacy : science and practice · 2023Pooled it
- Therapeutic drug monitoring of amikacin in Chinese premature infant: a population pharmacokinetic analysis and dosage optimization.BMC infectious diseases · 2025Article
- Causal effects of gut microbiota on sepsis and sepsis-related death: insights from genome-wide Mendelian randomization, single-cell RNA, bulk RNA sequencing, and network pharmacology.Journal of translational medicine · 2024Article
- Inoculum-Based Dosing: A Novel Concept for Combining Time with Concentration-Dependent Antibiotics to Optimize Clinical and Microbiological Outcomes in Severe Gram Negative Sepsis.Antibiotics (Basel, Switzerland) · 2023Review
- International survey of antibiotic dosing and monitoring in adult intensive care units.Critical care (London, England) · 2023Article
- Development of a Predictive Dosing Nomogram to Achieve PK/PD Targets of Amikacin Initial Dose in Critically Ill Patients: A Non-Parametric Approach.Antibiotics (Basel, Switzerland) · 2023Article
- Assessment of the Effects of a High Amikacin Dose on Plasma Peak Concentration in Critically Ill Children.Paediatric drugs · 2021Observational
- Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database.Annals of intensive care · 2020Article
- Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.Antimicrobial agents and chemotherapy · 2020Article
- The "Old" and the "New" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How.Frontiers in public health · 2019Review
- Predictors of insufficient peak amikacin concentration in critically ill patients on extracorporeal membrane oxygenation.Critical care (London, England) · 2018Observational
- Review
- Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.Clinical microbiology reviews · 2018Review
- Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications.Clinical pharmacokinetics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe therapeutic effect of aminoglycosides is highest and optimal when the peak plasma concentration (C
methodsThis was a prospective observational cohort study conducted in two intensive care units (ICU). Patients receiving amikacin at a loading dose of 30 mg/kg for severe sepsis or septic shock were enrolled in the cohort. The target C
resultsOver the study period, the amikacin C
conclusionsWith a loading dose of 30 mg/kg of amikacin, concentration was potentially suboptimal (C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.